Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens

Gynecologic Oncology

Volumn 88, Issue 3, 2003, Pages 351-357

  Ray Coquard, Isabelle ^a   Bachelot, Thomas ^a   Guastalla, Jean Paul ^a   Levy, Éric ^b   Tigaud, Jean Dominique ^c   Vincent, Pascal ^d   Dramais, Dominique ^e   Assouline, David ^f   Pujade Lauraine, Eric ^g  

^a CENTRE LÉON BÉRARD   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d INSTITUT SAINTE CATHERINE   (France)

^e CENTRE HOSPITALIER DE VALENCE   (France)

^f Clinique du Mail   (France)

^g HÔTEL DIEU   (France)

Author keywords

Advanced ovarian cancer; Chemotherapy; Epirubicin; Paclitaxel

Indexed keywords

ANTHRACYCLINE; CIMETIDINE; DEXCHLORPHENIRAMINE; EPIRUBICIN; PACLITAXEL; PLATINUM; PREDNISOLONE; RANITIDINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG INFUSION; DRUG TOLERANCE; FEASIBILITY STUDY; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHY; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0037342176     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(02)00151-8     Document Type: Article

References (23)

1. Ozols R.F., Young R.C. Chemotherapy of ovarian cancer. Semin Oncol. 18:1991;222-232.
2. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
3. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer a gynecologic oncology group study . J Clin Oncol. 18:2000;106-115.
4. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
5. Gore M.E., Fryatt I., Wiltshaw E., Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 36:1990;207-211.
6. Markman M., Reichman B., Hakes T., Jones W., Lewis J.L. Jr, Rubin S., et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer influence of a prior response to intravenous cisplatin . J Clin Oncol. 9:1991;1801-1805.
7. Conte P.F., Bruzzone M., Chiara S., Sertoli M.R., Daga M.G., Rubagotti A., et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol. 4:1986;965-971.
8. Omura G.A., Bundy B.N., Berek J.S., Curry S., Delgado G., Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma a Gynecologic Oncology Group Study . J Clin Oncol. 7:1989;457-465.
9. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia. Lancet 1987;2:353-9.
10. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project. J Clin Oncol 1991;9:1668-74.
11. Fanning J., Bennett T.Z., Hilgers R.D. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol. 80:1992;954-960.
12. A'Hern R.P., Gore M.E. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol. 13:1995;726-732.
13. Perry M.C. Appendix - WHO toxicity guidelines. Perry M.C. The chemotherapy sources book. 1st ed. 1992;1132-1144 Williams & Wilkins Inc, Baltimore.
14. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
15. Vergote I., Rustin G.J., Eisenhauer E.A., Kristensen G.B., Pujade-Lauraine E., Parmar M.K., et al. Re new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup . J Natl Cancer Inst. 92:2000;1534-1535.
16. Thigpen J.T., Vance R.B., Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer. 71:1993;1559-1564.
17. Kaplan E.C.M.P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;437-481.
18. Mantel N.H.W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:1959;719-748.
19. Trimble E.L., Adams J.D., Vena D., Hawkins M.J., Friedman M.A., Fisherman J.S., et al. Paclitaxel for platinum-refractory ovarian cancer results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103 . J Clin Oncol. 11:1993;2405-2410.
20. Vermorken J.B., Kobierska A., Chevallier B., Zanaboni F., Pawinski A., Bolis G. A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group. Ann Oncol. 11:2000;1035-1040.
21. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma a randomized phase III study of pegylated liposomal doxorubicin versus topotecan . J Clin Oncol. 19:2001;3312-3322.
22. Koechli O.R., Sevin B.U., Perras J.P., Chou T.C., Angioli R., Steren A., et al. Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay. Breast Cancer Res Treat. 28:1993;21-27.
23. du Bois, A., Weber, B., Pfister, J., Goupil, A., Wagner, U., Barats, J., et al. epirubicin/paclitaxel/carboplatin (TEC) vs. paclitaxel/carboplatin (TC) in first line treatment of ovarian cancer figo stages IIb-IV. Interim results of an AGO-GINECO Intergroup trial. ASCO 20, 202-202. 12-5-2001.